The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2022 | RTX-240: allogeneic RBCs drive expansion & trafficking of CD8+ T-cells & NK cells into the TME
Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses findings from a Phase I study evaluating RTX-240, an allogeneic cellular therapy genetically engineered to express high copy numbers of trimeric 4-1BBL and IL-15/IL-15Rα fusion proteins on the red blood cell (RBC) surface membrane in order to activate and expand CD8+ memory T-cells and NK cells. RTX-240 is well tolerated at all tested doses and leads to activation, expansion, and trafficking of memory CD8+ T cells and NK cells into the tumor microenvironment (TME). This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
